Dr Reddy’s Moves Ahead With Global Rituximab Filings
US FDA, EMA And MHRA Accept Firm’s Rituxan/MabThera Biosimilar Rival For Review
Dr Reddy’s has celebrated a “milestone” for its biosimilars business after disclosing that multiple regulators in Europe and the US have accepted its rituximab filings for review.
